Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first

ConclusionsNeoadjuvant Bevacizumab-based chemotherapy was associated with improved OS in patients who underwent liver resection of synchronous CRLM, especially in those who underwent primary tumor resection first.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research